Skip to main content
News Schmidt-Burgk 07.2021
The development team behind the LAMP-Seq method (l-r): Dr. Dr. Ricarda Schmithausen (Institute of Hygiene and Public Health), Prof. Dr. Jonathan Schmid-Burgk (Institute of Clinical Chemistry and Clinical Pharmacology), Dr. Kerstin Ludwig (Institute of Human Genetics) and Dr. Per Hoffmann (Institute of Human Genetics)
© F. Heyder / UKB

Publication

New corona mass test developed by Cluster member

Cluster member Jonathan Schmid-Burgk and colleagues developed a new corona test that is up to 100 times more sensitive than rapid antigen tests.

The "LAMP-Seq" test is based on sequencing technology and can analyze a large number of swabs simultaneously with similar high sensitivity to the commonly used qPCR test. The innovative method offers great potential, especially for systematic testing in day care centers, schools or companies. The results of the study on the new Corona test have been published in the renowned journal "Nature Biotechnology". WDR Lokalzeit from Bonn also reported about this new Corona test and talked to the scientists involved.


Read more in the UKB press release (german)
or watch the TV report from the WDR Lokalzeit (german):

Publication

Kerstin U. Ludwig, Ricarda M. Schmithausen, David Li, Max L. Jacobs, Ronja Hollstein, Katja Blumenstock, Jana Liebing, Mikolaj Slabicki, Amir Ben-Shmuel, Ofir Israeli, Shay Weiss, Thomas S. Ebert, Nir Paran, Wibke Rüdiger, Gero Wilbring, David Feldman, Bärbel Lippke, Nina Ishorst, Lara M. Hochfeld, Eva C. Beins, Ines H. Kaltheuner, Maximilian Schmitz, Aliona Wöhler, Manuel Döhla, Esther Sib, Marius Jentzsch, Jacob D. Borrajo, Jonathan Strecker, Julia Reinhardt, Brian Cleary, Matthias Geyer, Michael Hölzel, Rhiannon Macrae, Markus M. Nöthen, Per Hoffmann, Martin Exner, Aviv Regev, Feng Zhang, Jonathan L. Schmid-Burgk: "LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding", Nature Biotechnology,
https://www.nature.com/articles/s41587-021-00966-9

Related news

Symbol Image

Publication

Instructions for building antibodies decoded

—MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein in the myelin layer that surrounds the neurons in the brain. It is believed that these antibodies contribute to the destruction of this protective layer in the brain. Researchers at the University Hospital Bonn (UKB) and the Universities of Basel and Bonn, in collaboration with an international team, have now deciphered the construction plan of the anti-MOG antibodies.
View entry
News Icon

Publication

A fatal mix-up: how certain gut bacteria drive multiple sclerosis

—If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of multiple sclerosis, as researchers at the University of Basel, together with colleagues in Bonn, have shown in trials with mice. However, their results also open up opportunities for treatments that make use of the microbiome. The results have now been published in the journal Gut Microbes.
View entry
News Icon

Publication

New vulnerability of asthma immune cells discovered

—Why do certain immune cells remain permanently active in allergic asthma – even in an environment that should actually damage them? A team from the University Hospital Bonn (UKB) and the University of Bonn has discovered that these cells only survive because they activate a special antioxidant protection mechanism. When this mechanism is blocked, allergic inflammation in mouse models decreases significantly. The results have now been published in the scientific journal Immunity.
View entry

Back to the news overview